What series of products do egg-based organisms in Nanjing have?

Nanjing Ji Dan Biotechnology Co., Ltd. was established in March 2002. Is a new Sino-foreign joint venture biotechnology company, with diagnostic reagents and medical devices as its main supporting industries. The company is located in Nanjing Zhongshan Science and Technology Park, covering an area of more than 40 mu, with a total construction area of 1.7 million square meters. It has first-class production facilities and equipment, and the GMP workshop built according to national standards has reached 65,438+0,000 square meters. At present, the company has nearly 20 national patents. 20 1 1 in may, the company sucCEssfully passed the quality management system certification and ce certification of TUV ISO 13485 in Rhine. Up to now, basic egg biology has developed into a modern high-tech enterprise integrating professional research and development, production and sales.

We have the brand of "egg-based organism", and our products mainly cover cardiovascular and cerebrovascular diseases, tumors, kidneys, infectious diseases and other fields. We have a series of market-leading cardiovascular marker detection kits and immunoquantitative analyzers. In 20 1 1 year, we established the bedside rapid diagnosis engineering technology center, which has several technical platforms and can be used for the research of bedside rapid diagnosis instruments and reagents. At the same time, the company also independently established a high-level genetic engineering and antibody engineering platform for the research of antibody drugs.

The company adopts the business strategy of focusing on developing new products and expanding the production scale and market share of the original products. In China, it has an extensive distribution network and professional marketing team, nearly 200 salespeople, nearly 50 strategic partners, more than 200 dealers and more than 800 hospital users in China, forming a nationwide sales network. At the same time, the company's products are exported to Europe, America, Asia and Africa. In the future, egg-based organisms will seize new opportunities, meet new challenges, aim at becoming a biotechnology company with international competitiveness, insist on independent innovation as an inexhaustible motive force for the company's survival and development, and strive to build a clinical testing system and antibody drugs with independent intellectual property rights and international advantages, so as to contribute to the biomedical industry in China and serve human health.